BIIB vs NVS
Biogen vs Novartis AG — AI-powered side-by-side comparison
| Metric | BIIB | NVS |
|---|
| AI Score |
67
|
73
|
| Price |
$208.02
|
$156.34
|
| P/E Ratio |
36.61×
|
23.66×
|
| ROE |
7.1%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.7%
|
74.3%
|
| Debt / Equity |
0.44×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
56.7
|
55.8
|
| Beta |
0.158
|
0.46
|
| Expected Upside |
+5.2%
|
+2.7%
|
AI Committee View
Current Innellis committee reasoning for BIIB versus NVS.
NVS leads by 6 points.
NVS scores 73/100 (Buy) versus BIIB at 67/100 (Buy).
BIIB Committee View
80% agreement
5 analysts
The primary driver is news sentiment is positive (+0.42 across 47 articles, 14d). The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical